News >

Atezolizumab Plus Bevacizumab Extends Survival in Frontline HCC

Jason M. Broderick @jasoncology
Published: Friday, Nov 22, 2019

Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development of Genentech (Roche)

Levi Garraway, MD, PhD

The frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) reduced the risk of disease progression or death by 42% compared with sorafenib (Nexavar) in patients with unresectable hepatocellular carcinoma (HCC), according to topline results from the phase III IMbrave150 trial presented at the 2019 ESMO Asia Congress.1

The 65% ORR comprised a complete response rate of 4% (n = 1) and a partial response rate of 61% (n = 14). Additionally, 7 (30%) patients had stable disease and 1 (4%) patient had progressive disease. A disease control rate of ≥6 months was reported for 16 (70%) patients.

References          

  1. Genentech presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer [news release]. South San Francisco, CA: Genentech. Posted November 22, 2019. bit.ly/35rZfGc. Accessed November 22, 2019.       
  2. Stein S, Pishvaian MJ, Lee MS, et al. Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).  J Clin Oncol. 2018;36(suppl 15; abstr 4074). doi: 10.1200/JCO.2018.36.15_suppl.4074.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x